1,187
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Guidelines for the Pharmacologic Treatment of COPD 2023: Canada versus GOLD

Article: 2292613 | Received 09 Nov 2023, Accepted 01 Dec 2023, Published online: 08 Feb 2024
 

Declaration of interest

The authors declare there is no Complete of Interest at this study.

Financial disclosures

The author attended scientific advisory committee meetings or received speaking fees from AstraZeneca, Atara, Boehringer-Ingelheim, Bristol-Myers-Squibb, Merck, Novartis, Panalgo, Pfizer and Seqirus.

Funding information

This work is not funded. Pr. Suissa is the recipient of the Distinguished James McGill Professorship award.

Disclosure statement

No potential conflict of interest was reported by the author(s).